SCHEMBL1817898

SCHEMBL1817898

O=Cc1cccc2cc3cccc(C=O)c3cc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
LMNA P02545 1/20 0.48
THRB P10828 1/20 0.48
BLM P54132 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
CYP2A6 P11509 1/20 0.45
ERN1 O75460 4/20 0.41
ALDH1A1 P00352 6/20 0.41
CYP1A2 P05177 4/20 0.41
MITF O75030 1/20 0.41
MAPT P10636 1/20 0.41
CYP2C9 P11712 1/20 0.41
PKM P14618 1/20 0.41
MAPK1 P28482 1/20 0.41
RAB9A P51151 1/20 0.41
CCR6 P51684 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
TRIM24 O15164 2/20 0.39
TRIM33 Q9UPN9 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29392367 0.91 ALDH1A1 (0.50) MEN1KMT2ALMNATHRBBLM
SCHEMBL39718 0.91 ALDH1A1 (0.50) MEN1KMT2ALMNATHRBBLM
SCHEMBL30446471 0.89 ALDH1A1 (0.49) MEN1KMT2ALMNATHRBBLM
SCHEMBL548781 0.89 ALDH1A1 (0.49) MEN1KMT2ALMNATHRBBLM
SCHEMBL548710 0.89 ALDH1A1 (0.49) MEN1KMT2ALMNATHRBBLM
SCHEMBL31340003 0.89 ALDH1A1 (0.49) MEN1KMT2ALMNATHRBBLM
SCHEMBL7036744 0.88 MEN1 (0.46) MEN1KMT2ALMNATHRBBLM
SCHEMBL5746410 0.88 ALDH1A1 (0.42) MEN1KMT2ALMNATHRBBLM
Methyl Alcohol SCHEMBL27597852 0.86 ALDH1A1 (0.46) MEN1KMT2ALMNATHRBBLM
SCHEMBL31317593 0.85 ERN1 (0.43) MEN1KMT2ALMNATHRBBLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120056488-A Preparation method of copper-free and steel-free carbon fiber composite friction plate applied to electric bicycle 浙江万赛汽车零部件股份有限公司 2025-05-30 CN disclosed
US-10392395-B2 Nitrogen-containing aromatic compounds and metal complexes SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2019-08-27 US disclosed
US-10392395-B2 Nitrogen-containing aromatic compounds and metal complexes SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2019-08-27 US disclosed
EP-2493890-B1 NITROGEN-CONTAINING AROMATIC COMPOUNDS AND METAL COMPLEXES SUMITOMO CHEMICAL CO (JP) 2018-03-21 EP disclosed
CN-102666547-B Nitrogen-containing aromatic compound and metal complex SUMITOMO CHEMICAL CO.,LTD. (JP) 2016-05-04 CN disclosed
US-8993806-B2 Organic porous materials comprising shape-persistent three-dimensional molecular cage building blocks THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) 2015-03-31 US disclosed
US-8993806-B2 Organic porous materials comprising shape-persistent three-dimensional molecular cage building blocks THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) 2015-03-31 US disclosed
US-20130047849-A1 Organic Porous Materials Comprising Shape-Persistent Three-Dimensional Molecular Cage Building Blocks THE REGENTS OF THE UNIVERSITY OF COLORADO 2013-02-28 US disclosed
US-20130047849-A1 Organic Porous Materials Comprising Shape-Persistent Three-Dimensional Molecular Cage Building Blocks THE REGENTS OF THE UNIVERSITY OF COLORADO 2013-02-28 US disclosed
US-20120270141-A1 NITROGEN-CONTAINING AROMATIC COMPOUNDS AND METAL COMPLEXES MAX PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) 2012-10-25 US disclosed
WO-2011052805-A1 NITROGEN-CONTAINING AROMATIC COMPOUNDS AND METAL COMPLEXES SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-05-05 WO disclosed
US-6610663-B2 Antisense compound with targeting and RNA cleaving moieties, preferably an imidazole functionality conjugated to the targeting oligonucleotide via linkers ISIS PHARMACEUTICALS, INC. 2003-08-26 US disclosed
US-20020160972-A1 Compositions and methods for modulating RNA ISIS PHARMACEUTICALS, INC. 2002-10-31 US disclosed
US-6358931-B1 OLIGONUCLETIDE CONJUGATED TO IMIDAZOLE; INTERCALATION AND COORDINATION COMPOUNDS; MEDICAL DIAGNOSIS, GENE THERAPY; ANTISENSE AGENTS ISIS PHARMACEUTICALS, INC. 2002-03-19 US disclosed
EP-0656790-A1 COMPOSITIONS AND METHODS FOR MODULATING RNA ISIS PHARMACEUTICALS, INC. (US) 1995-06-14 EP disclosed
WO-1993017717-A1 COMPOSITIONS AND METHODS FOR MODULATING RNA ISIS PHARMACEUTICALS, INC. (US) 1993-09-16 WO disclosed
EP-0041675-B1 4-HALOGEN-5-(TRICHLOROMETHYL-PHENYL)-OXAZOLE DERIVATIVES, PROCESS FOR PREPARING THEM AND RADIATION-SENSITIVE COMPOSITIONS CONTAINING THEM HOECHST AKTIENGESELLSCHAFT (DE) 1985-12-11 EP disclosed
US-4371607-A 4-Halogeno-5-(halogenomethyl-phenyl)-oxazole derivatives, a process for the preparation thereof, and radiation-sensitive compositions containing these derivatives HOECHST AKTIENGESELLSCHAFT (DE) 1983-02-01 US disclosed
EP-0041675-A2 4-Halogen-5-(trichloromethyl-phenyl)-oxazole derivatives, process for preparing them and radiation-sensitive compositions containing them HOECHST AKTIENGESELLSCHAFT (DE) 1981-12-16 EP disclosed
US-4017313-A Photosensitive composition containing a leuco dye, a photosensitizer, an aromatic aldehyde and a secondary or tertiary amine and the use thereof in a direct-print process E. I. DU PONT DE NEMOURS AND COMPANY (US) 1977-04-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020160972-A1 Compositions and methods for modulating RNA RNGTT, NSUN3, NSUN2 MEN1 3459/4885KMT2A 1080/4885LMNA 375/4885
US-20120270141-A1 NITROGEN-CONTAINING AROMATIC COMPOUNDS AND METAL COMPLEXES TYR, MT-CO2, SOD1 MEN1 2740/4885KMT2A 1041/4885LMNA 3383/4885
US-10392395-B2 Nitrogen-containing aromatic compounds and metal complexes TYR, MT-CO2, SOD1 MEN1 2740/4885KMT2A 1041/4885LMNA 3383/4885
US-20130047849-A1 Organic Porous Materials Comprising Shape-Persistent Three-Dimensional Molecular Cage Building Blocks CAPG, NCBP1, ORC3 MEN1 4578/4885KMT2A 4326/4885LMNA 3567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.